Key facts
- It has raised $2.6M; the latest was Later Stage VC ($500K) in Dec 2025.
- Notable investors include Icehouse Ventures, Ada Ventures, Callaghan Innovation, Custos Privatstiftung, David Ross — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Helico
- ·The full record, as it builds
Funding rounds
No funding rounds for Helico are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Helico
Operator of an integrated biopharmaceutical company intended to make plants able to manufacture lifesaving medicine. The company's technology specializes in producing therapeutic compounds from plants to produce a targeted biologic or biosimilar and to generate better plant models, custom-made for the protein of interest to allow increased yields, enabling patients to get the most needed medicines with low-cost agriculture.
- Sector
- Healthcare
- HQ
- Auckland, New Zealand
- Founded
- 2020
- Employees
- 5
- Website
- helico.bio/
- Ownership
- Privately Held (backing)
Helico doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Helico shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Helico in its N-PORT filings yet. We sweep new filings monthly.